This retrospective study, including 135 metastatic melanoma patients who received consecutive treatments with BRAF/MEKi and CPI, or vice versa, provides evidence that front-line treatment with CPI is associated with favorable tumor control and overall survival in patients with BRAF-mutant melanoma. The gene discussed is BRAF; the disease is metastatic melanoma.